Every question you ask can be matched with a suitable answer
Leave me a message
We take every suggestion of yours seriously
Wechat
Tan Xiaojun
·Senior reproductive medicine expert
·Postdoctoral fellow at Peking University
·PhD candidate at Xiangya School of Medicine, Central South
University
·Master’s tutor at Central South University
· Master's degree candidate in reproductive
medicine at the University of South China
· Professional training at Huazhong University
of Science and Technology and Tongji
Hospital Reproductive Center
Expertise:
diagnosis and treatment of infertility, first/second/third generation IVF (including
egg/sperm donation), microsperm retrieval, embryo freezing and resuscitation, artificial
insemination (including husband's sperm and sperm donation), paternity testing, chromosomal
disease
diagnosis, high-throughput gene sequencing, endometrial receptivity gene testing and other
clinical
technology applications. Many of these technologies are at the leading level both domestically
and
internationally.
How about a test tube from Chinese to Kyrgyzstan? Six key questions are thoroughly explained: who is suitable, how to go through the process, and what to pay attention to.
How about a test tube from Chinese to Kyrgyzstan? This article is disassembled from the perspectives of suitable population, diagnosis and treatment process, technical links, visa and communication costs, etc., to help pregnant families more rationally judge whether it is worth going.
How about Chinese going to Kyrgyzstan for test tubes? Look at the essence first, not the "country name" first.
When many people search this question for the first time, what they really want to ask is not "Is Kyrgyzstan good", but: Is it worthwhile, unstable and suitable for them to go there to make test tubes?
From the first-principles point of view, the core of IVF is never "in which country", but four things: whether the doctor's judgment on the cause is accurate, whether the laboratory is stable, whether the promotion and transplantation scheme match, and whether the cross-border medical treatment is smooth. * * The country is only an external variable, and the medical team and implementation details are the core of the decision.
Medically, infertility is not a minority phenomenon. According to the estimate released by the World Health Organization in 2023, about one in every six people of childbearing age in the world has experienced infertility. * * This means that the growth of cross-border demand for assisted reproduction is essentially an overflow of demand for medical treatment, rather than a simple "going abroad fever".
Which China families will consider going to Kyrgyzstan to do test tubes?
From the perspective of realistic decision-making, considering the population in Kyrgyzstan is usually not the result of "randomly choosing a country", but the result after going to a certain stage. There are several common types:
The first category is people who have done basic examinations in China, even had experience in promoting excretion or transplantation, but want to change the cross-border diagnosis and treatment path.
The second category is people who are sensitive to time and cost, and hope to compress the consultation, filing and weekly arrangement more compactly.
The third category is people who are pregnant at an advanced age, have repeatedly failed and hope to complete a more systematic assessment as soon as possible.
The fourth category is people who are more sensitive to language consultation, travel distance and visa operation difficulty, and will pay more attention to whether the medical link is easy to implement.
Here, we should directly point out a common misunderstanding: * * Being old doesn't mean going abroad, and being young doesn't mean being easy to succeed. * * Female fertility will decline with age. According to the relevant opinions of the American College of Obstetricians and Gynecologists, female fertility will gradually decline from about 32 years old, and the decline will be more obvious after 37 years old; If you are over 35 years old and have not been pregnant for 6 months, you should usually enter the system evaluation as soon as possible.
* * Expert tip: * * If there are more than two abnormalities in the four items: age, ovarian reserve, semen quality and uterine environment, then "continuing to wait" is often not a neutral choice, but a time window to continue to consume.
Technically, the focus of test tubes in Kyrgyzstan is not "whether there is technology", but "whether the technology is standardized and landed"
Many users are concerned about: Can we do the first, second and embryo screening there?
From the general technical path of assisted reproduction, test tubes are not mysterious, and the core links include: promoting ovulation and taking eggs, in vitro fertilization, embryo culture, embryo genetic testing if necessary, transplantation and corpus luteum support. What really affects the clinical experience is not how many technical terms are written in the organization propaganda, but whether there are clear indications, whether genetic counseling is done enough, and whether laboratory standards are implemented in place.
Taking PGT as an example, the good practice suggestions issued by the European Society of Human Reproduction and Embryology (ESHRE) repeatedly emphasize that **PGT is not a general upgrade item that everyone should do, but should be based on the complete process of patient selection, genetic counseling and pregnancy follow-up. * * In other words, whether you can do it or not is one thing, and whether you should do it, how to do it, and to whom is another matter.
That's why, to judge "how about Chinese's test tube going to Kyrgyzstan", we should not only look at the "projects that can be done" on the publicity page, but also look at four harder indicators:
First, whether there is a complete initial assessment;
Second, whether the ovulation promotion scheme is adjusted individually according to age, AMH, AFC and hormone level;
Third, whether the laboratory is stable and whether embryo culture is standardized;
Fourth, whether intima, hormone, inflammation, immunity and male factors are really included in the analysis before transplantation.
* * Expert tip: **PGT can help identify some risks of chromosomal abnormalities, but it is not a commitment tool for live birth results, nor can it replace the comprehensive assessment of uterine environment, embryo quality and overall pregnancy risk.
From the process point of view, the difficulty in Chinese's cross-border trip to Kyrgyzstan to do test tubes is not the medical treatment itself, but the connection.
Many people think that the difficulty of the process lies in the hospital, but in fact it often lies in the "front and rear end fracture". A more realistic cross-border process usually goes like this:
First, complete the basic examination in China, including female hormone, AMH, B-ultrasound follicular monitoring, infectious disease screening, and male semen analysis.
Then overseas institutions will judge whether it is necessary to make up the project and give suggestions for the coming week;
Then deal with visa, air ticket, accommodation, translation or accompanying medical arrangements;
After arriving at the hospital, check, promote ovulation, take eggs, fertilize, cultivate, transplant or arrange frozen embryos;
After returning to China, continue corpus luteum support, blood test and follow-up in early pregnancy.
Therefore, what really affects the experience is not whether you can do a test tube, but whether your domestic examination can be successfully connected, whether there are repeated examinations, whether the communication between doctors is clear, and who will undertake the follow-up after returning home.
On the travel level, the official electronic visa platform in Kyrgyzstan shows that tourist or business visas can be applied online, and ordinary passports can choose the corresponding passport type in the system; The platform also states that online application has the same entry effect as traditional sticker visa. China Consular Service Network mentioned that ordinary passport holders generally still need to apply for visas; Another special case is that from October 21st, 2023, citizens of China who hold long-term valid visas for more than three years from the United States, Britain or Schengen countries can enter the country visa-free through Bishkek Manas International Airport, and their single stay will not exceed seven days.
This means that * * for China patients, the "accessibility" of Kyrgyzstan is not bad, but accessibility is not equal to medical adaptability. * * The visa is convenient, which only means that it is possible to go, but it does not mean that it is definitely suitable to go.
What are the advantages and risks of Chinese going to Kyrgyzstan for test tubes?
From an objective point of view, its advantages are mainly reflected in three points.
First, the decision-making chain is relatively short. * * For some cross-border medical patients, as long as the preliminary information is complete, it will be more direct to file, enter the week and connect the itinerary than to explore it by yourself.
Second, the burden of geography and time difference is usually lighter than that of Europe and America. * * This will affect the round-trip arrangement, escort cost and communication fatigue.
Third, for some people who want to start the program as soon as possible, it is easier to form a closed loop at the implementation level.
But the disadvantages can't be avoided.
First, * * information transparency is the core risk. * * What users are most afraid of is not being expensive, but not being able to see clearly: what is the level of the laboratory, who is the real attending, how to recover after failure, and who is responsible for complications.
Second, cross-border follow-up visits are weak. * * Taking eggs, returning to China after transplantation, luteal support, early pregnancy, and abnormal bleeding management all need domestic doctors to continue to take over.
Third, * * language and cultural communication will amplify errors. * * Once medical communication is relayed, details are easily lost.
Fourth, it is a cognitive risk to misunderstand "foreign countries" as "easier to succeed". * * The underlying variables, such as age, ovarian reserve, sperm quality and uterine conditions, will not change automatically because of changing countries.
Several high-frequency questions about "How about Chinese going to Kyrgyzstan for test tubes"
Question 1: Will the success rate be significantly improved as long as you go overseas?
Not necessarily. The key factors affecting the outcome are still age, embryo quality, uterine environment and individual etiology. Especially for elderly patients, age itself is a hard variable. According to the patient data of American Reproductive Medicine Association, the chances of IVF pregnancy by using self-fertilized eggs at the age of 43 have obviously decreased, and the chances of success by self-fertilized eggs are even lower after the age of 45, so it is often necessary to evaluate the scheme more realistically in clinic.
Question 2: Is Kyrgyzstan suitable for people who make test tubes for the first time?
It may be suitable, but it is not naturally suitable. People who do it for the first time should pay more attention to whether they can get a complete diagnosis and treatment explanation, whether they know why each step is done, and whether there is a resumption mechanism after failure. The first time I saw a doctor, I was most afraid of being pushed away by the process.
Question 3: Is it better if the process is fast?
No. Fast process only means high organizational efficiency; What is more important in medicine is to check whether it is sufficient, whether the plan of promoting excretion is reasonable, and whether the transplant window is judged accurately. Too fast but under-evaluated may also bury the risk of failure.
Question 4: Who is less suitable for rushing across the border?
People with serious medical diseases, unexplained recurrent abortion, obviously abnormal uterine factors, complicated sperm problems without systematic evaluation, and low tolerance for cross-border communication are not suitable for rushing to start just by publicity.
summary
How about a test tube from Chinese to Kyrgyzstan? The conclusion is not "good" or "bad", but "optional for some people, provided that the information is sufficient, the cause is clear, the organization is transparent and the connection is smooth".
If you only look at the name of the country, you will never be able to answer this question;
If we go back to medical logic, the answer will be much clearer:
Look at age and ovarian reserve first;
Look at the male factor and the uterine environment;
See if the hospital can give a clear plan;
Finally, it depends on whether travel, visas and accompanying doctors are easy to implement.
What really deserves attention is not where to do it, but whether you have entered a diagnosis and treatment system with transparent information and stable implementation at the right time and with the right plan.
Common aliases:Kyrgyzstan Tulip Reproductive Center, Tulip IVF, Tulip Reproductive Center, Tulip Hospital, Kyrgyz Tulip Reproductive Center, Kyrgyz Tulip Hospital
